Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

Clock-Calendar_173563493_1200.jpg

The clock could be ticking on using cannabidiols in dietary supplements available in the US without submitting new dietary ingredient notifications that the Food and Drug Administration agrees show safety for the ingredient's intended uses.

The agency's recent statement that it is not aware of evidence supporting CBD as generally recognized as safe among qualified...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation